Barclays’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-2,850
Closed -$151K 5276
2020
Q3
$151K Sell
2,850
-571
-17% -$35.2K ﹤0.01% 4027
2020
Q2
$210K Buy
3,421
+1,386
+68% +$80.2K ﹤0.01% 4039
2020
Q1
$115K Sell
2,035
-4,100
-67% -$234K ﹤0.01% 4712
2019
Q4
$349K Buy
6,135
+2,207
+56% +$117K ﹤0.01% 4592
2019
Q3
$210K Sell
3,928
-27
-0.7% -$1.57K ﹤0.01% 4929
2019
Q2
$236K Buy
3,955
+1,902
+93% +$120K ﹤0.01% 4965
2019
Q1
$128K Buy
2,053
+1,878
+1,073% +$124K ﹤0.01% 5174
2018
Q4
$11K Sell
175
-1,981
-92% -$118K ﹤0.01% 6151
2018
Q3
$126K Buy
2,156
+1,742
+421% +$88.9K ﹤0.01% 5359
2018
Q2
$19K Sell
414
-766
-65% -$32.9K ﹤0.01% 6226
2018
Q1
$52K Buy
1,180
+284
+32% +$11.9K ﹤0.01% 5883
2017
Q4
$39K Buy
896
+765
+584% +$34.4K ﹤0.01% 5903
2017
Q3
$6K Sell
131
-1,220
-90% -$58.4K ﹤0.01% 6383
2017
Q2
$66K Sell
1,351
-5,774
-81% -$302K ﹤0.01% 5184
2017
Q1
$390K Buy
7,125
+4,725
+197% +$250K ﹤0.01% 3656
2016
Q4
$134K Buy
2,400
+2,365
+6,757% +$114K ﹤0.01% 4541
2016
Q3
$2K Buy
+35
New +$1.41K ﹤0.01% 6308
2016
Q1
Sell
-761
Closed -$32K 6571
2015
Q4
$32K Buy
761
+590
+345% +$29.6K ﹤0.01% 5018
2015
Q3
$7K Sell
171
-132
-44% -$7.12K ﹤0.01% 5945
2015
Q2
$16K Sell
303
-814
-73% -$34.7K ﹤0.01% 5820
2015
Q1
$45K Buy
1,117
+911
+442% +$35.7K ﹤0.01% 5364
2014
Q4
$8K Sell
206
-582
-74% -$22.2K ﹤0.01% 6844
2014
Q3
$27K Buy
788
+708
+885% +$20.8K ﹤0.01% 6305
2014
Q2
$2K Buy
+80
New +$2.08K ﹤0.01% 7438
2014
Q1
Sell
-401
Closed -$8K 7784
2013
Q4
$8K Buy
401
+400
+40,000% +$8.19K ﹤0.01% 7072
2013
Q3
$0 Sell
1
-5,288
-100% -$93.7K ﹤0.01% 7696
2013
Q2
$82K Buy
+5,289
New +$85.1K ﹤0.01% 5958

Other funds holding BSTC

Barclays's BSTC Position: Q4 2020 in Review

Barclays sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2020, closing a stake of 2,850 shares — an estimated $151K sold.

Barclays first reported a position in BSTC in Q2 2013 and held it in 27 quarters. The position peaked at $390K in Q1 2017. 1 fund tracked by Wall St. Rank holds BSTC as of Q4 2020.

  • Barclays reported no remaining BioSpecifics Technologies Corp. position as of Q4 2020 after selling out during the quarter.
  • Barclays sold 2,850 BioSpecifics Technologies Corp. shares in Q4 2020, an estimated $151K.
  • Barclays first reported a position in BioSpecifics Technologies Corp. in Q2 2013 and held it in 27 quarters.
  • Barclays's BioSpecifics Technologies Corp. position peaked at $390K in Q1 2017.
  • 1 fund tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2020.

Based on Barclays's 13F filing for Q4 2020, filed 11 Feb 2021.